The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.
Menlo Park, CA's Avalanche Biotechnologies pulled off a $102 million Wall Street debut, planning to spend its new cash on a pipeline of gene therapies for ocular diseases.
Biotech luminary Sage Therapeutics is boosting the size of its planned IPO, upping its share offering and expected price range as investors look to its Wall Street debut as a bellwether for the industry.
San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.
After two consecutive quarters of mostly bullish biotech debuts, two drugmakers are lining up IPOs in hopes the market stays drug-friendly, seeking a combined $126.5 million to bankroll treatments for cancer and metabolic disease.
It takes a scorecard to keep up with the biotech IPO action these days. Four of the 8 companies planning to go public in the U.S. this week are biotechs, including Minerva and Syndax, and the crush of companies at the Nasdaq gate is making it increasingly hard for all of them to find a large enough group of investors to back their play.
Even though the biotech IPO market has been sputtering under the weight of a wave of new offerings and some heightened skepticism of what's being put in front of investors these days, two more biotechs have laid out plans to raise a total of some $150 million.
Fresh off its latest R&D partnership, Dutch antibody specialist arGEN-X is planning to go public in Brussels, looking to raise cash and advance its proprietary pipeline.
Syndax Pharmaceuticals is looking to raise $69 million in an IPO, planning to move 4.3 million shares at between $13 and $15 apiece.
Ardelyx retained U.S. co-promotion rights for tenapanor when it did its deal with AstraZeneca back in 2012.